Companies Lexicon Pharmaceuticals, Inc
Lexicon Pharmaceuticals (LXRX): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Lexicon Pharmaceuticals, Inc’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers6th pct.Of 22 peer CEOs
CEO pay, last three years
- $2,835,589FY2024
- $3,553,953FY2025
CEO total pay was $3,553,953 in fiscal 2025, up from $2,835,589 in fiscal 2024.
FY2025: salary $650,576 · bonus $483,822 · stock awards $1,049,304 · option awards $1,355,231
Executives and directors
Craig Granowitz · SVPBrian Crum · General CounselMichael Exton · CEOScott Coiante · CFOWendy McDermott · SVPChristopher J. Sobecki · Independent DirectorDiane E. Sullivan · Independent DirectorIvan H. Cheung · Independent DirectorJudith L. Swain, M.D · Independent DirectorPhilippe J. Amouyal · Independent DirectorRaymond Debbane · Chair of the BoardSamuel L. Barker, Ph.D · Independent Director
Frequently asked questions
Who was the highest-paid executive at Lexicon Pharmaceuticals, Inc in fiscal 2025?
As disclosed, Michael Exton (Chief Executive Officer and Director) was the highest-paid executive at Lexicon Pharmaceuticals, Inc in fiscal 2025, with total compensation of $3,553,953.
How does Lexicon Pharmaceuticals, Inc's chief executive pay compare to its disclosed peer group?
As disclosed, Michael Exton's total compensation ranked at the 6th percentile of Lexicon Pharmaceuticals, Inc's disclosed peer group.
What is Lexicon Pharmaceuticals, Inc's CEO-to-median employee pay ratio?
As disclosed, Lexicon Pharmaceuticals, Inc's CEO-to-median employee pay ratio was 13:1.
How did shareholders vote on Lexicon Pharmaceuticals, Inc's executive compensation?
As disclosed, 97.7% of shareholders supported Lexicon Pharmaceuticals, Inc's executive compensation in the latest say-on-pay vote.
How much does Lexicon Pharmaceuticals, Inc spend in total on board compensation for fiscal 2025?
As disclosed, Lexicon Pharmaceuticals, Inc reported total board compensation of $848,612 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Michael Exton | $650,576 | $483,822 | $1,049,304 | $1,355,231 | $0 | $0 | $15,020 | $3,553,953 |
| Chief Executive Officer and Director | ||||||||
| Craig Granowitz | 519,344 | 253,971 | 421,712 | 544,662 | 0 | 0 | 16,220 | 1,755,909 |
| Senior Vice President and Chief Medical Officer | ||||||||
| Scott Coiante | 444,172 | 187,200 | 334,093 | 577,866 | 0 | 0 | 14,915 | 1,558,246 |
| Senior Vice President and Chief Financial Officer | ||||||||
| Brian Crum | 489,926 | 180,035 | 354,791 | 458,227 | 0 | 0 | 17,405 | 1,500,384 |
| Senior Vice President and General Counsel | ||||||||
| Wendy McDermott | 415,758 | 149,835 | 301,060 | 388,840 | 0 | 0 | 14,853 | 1,270,346 |
| Senior Vice President, Human Resources | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Michael Exton | $3,553,953 | $2,835,589 | — | ↑ +718,364 |
| Craig Granowitz | 1,755,909 | 1,588,383 | 1,534,823 | ↑ +167,526 |
| Scott Coiante | 1,558,246 | — | — | — |
| Brian Crum | 1,500,384 | 1,430,607 | 1,421,275 | ↑ +69,777 |
| Wendy McDermott | 1,270,346 | 1,111,711 | 1,120,676 | ↑ +158,635 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Lexicon seeks to attract and retain key executives and motivate management to enhance long-term stockholder value by targeting total cash compensation (base salary plus annual cash bonus target) and total direct compensation at or near the median of a peer group of biopharmaceutical companies, contingent on company and individual performance and prevailing financial conditions. The committee allocates a greater percentage of total direct compensation to long-term stock-based incentive awards to reinforce alignment of interests between officers and stockholders.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer & Partners, LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | false |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Scott Coiante | OPTION | 2025-01-02 | — | — | 230,000 | — | $146,365 |
| Brian Crum | OPTION | 2025-02-13 | — | — | 765,730 | — | 458,227 |
| Wendy McDermott | OPTION | 2025-02-13 | — | — | 649,780 | — | 388,840 |
| Scott Coiante | OPTION | 2025-02-13 | — | — | 721,070 | — | 431,501 |
| Michael Exton | RSU | 2025-02-13 | — | — | 1,509,790 | — | 1,049,304 |
| Brian Crum | RSU | 2025-02-13 | — | — | 510,490 | — | 354,791 |
| Michael Exton | OPTION | 2025-02-13 | — | — | 2,264,690 | — | 1,355,231 |
| Craig Granowitz | OPTION | 2025-02-13 | — | — | 910,170 | — | 544,662 |
| Craig Granowitz | RSU | 2025-02-13 | — | — | 606,780 | — | 421,712 |
| Scott Coiante | RSU | 2025-02-13 | — | — | 480,710 | — | 334,093 |
| Wendy McDermott | RSU | 2025-02-13 | — | — | 433,180 | — | 301,060 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Scott Coiante | $334,093 | $0 | $577,866 | 0.0% |
| Brian Crum | 354,791 | 0 | 458,227 | 0.0% |
| Wendy McDermott | 301,060 | 0 | 388,840 | 0.0% |
| Michael Exton | 1,049,304 | 0 | 1,355,231 | 0.0% |
| Craig Granowitz | 421,712 | 0 | 544,662 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Wendy McDermott | Option | 1,774 | 3.94 | — |
| Wendy McDermott | Option | 7,104 | 3.2 | — |
| Brian Crum | Option | 9,786 | 3.2 | — |
| Craig Granowitz | Option | 10,468 | 3.2 | — |
| Wendy McDermott | RSU | 27,697 | — | 31,852 |
| Brian Crum | RSU | 33,457 | — | 38,476 |
| Craig Granowitz | RSU | 35,790 | — | 41,159 |
| Wendy McDermott | Option | 72,702 | 2.43 | — |
| Wendy McDermott | Option | 85,012 | 2.15 | — |
| Brian Crum | Option | 87,818 | 2.43 | — |
| Craig Granowitz | Option | 93,940 | 2.43 | — |
| Wendy McDermott | RSU | 104,633 | — | 120,328 |
| Brian Crum | Option | 112,749 | 2.15 | — |
| Craig Granowitz | Option | 120,614 | 2.15 | — |
| Brian Crum | RSU | 138,773 | — | 159,589 |
| Craig Granowitz | RSU | 148,453 | — | 170,721 |
| Scott Coiante | Option | 230,000 | 0.74 | — |
| Wendy McDermott | RSU | 433,180 | — | 498,157 |
| Scott Coiante | RSU | 480,710 | — | 552,817 |
| Brian Crum | RSU | 510,490 | — | 587,064 |
| Craig Granowitz | RSU | 606,780 | — | 697,797 |
| Wendy McDermott | Option | 649,780 | 0.7 | — |
| Scott Coiante | Option | 721,070 | 0.7 | — |
| Brian Crum | Option | 765,730 | 0.7 | — |
| Craig Granowitz | Option | 910,170 | 0.7 | — |
| Michael Exton | Option | 1,081,769 | 1.67 | — |
| Michael Exton | RSU | 1,509,790 | — | 1,736,259 |
| Michael Exton | Option | 2,264,690 | 0.7 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Raymond DebbaneIndependent · Board Chair · Corporate Governance (Chair) | $85,000 | $55,516 | $55,815 | — | $0 | $196,331 |
| Samuel L. Barker, Ph.DIndependent · Audit (Chair) · Compensation | 77,500 | 55,516 | 55,815 | — | 0 | 188,831 |
| Philippe J. AmouyalIndependent · Compensation (Chair) · Corporate Governance | 65,000 | 55,516 | 55,815 | — | 0 | 176,331 |
| Judith L. Swain, M.DIndependent · Compensation · Corporate Governance | 62,500 | 55,516 | 55,815 | — | 0 | 173,831 |
| Ivan H. CheungIndependent · Audit | 60,000 | 55,516 | 55,815 | — | 0 | 171,331 |
| Diane E. SullivanIndependent · Audit | 60,000 | 55,516 | 55,815 | — | 0 | 171,331 |
| Christopher J. SobeckiIndependent · Corporate Governance | 50,000 | 55,516 | 55,815 | — | 0 | 161,331 |
| Michael S. Exton, Ph.DEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $460,000 |
| Equity awards (grant-date value) | $388,612 |
| All other compensation | $0 |
| Total cost of the board | $848,612 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Lexicon Pharmaceuticals as a peer
Companies that benchmark against LXRX
6 companies name LXRX as a compensation peer
- Aurinia Pharmaceuticals Inc.AUPHFY2025
- ENANTA PHARMACEUTICALS INCENTAFY2025
- Evofem Biosciences, Inc.EVFMFY2024
- HERON THERAPEUTICS, INC. /DE/HRTXFY2025
- Syndax Pharmaceuticals IncSNDXFY2025
- Vanda Pharmaceuticals Inc.VNDAFY2025
Each company listed discloses LXRX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named LXRX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
ANAB AnaptysBio, Inc.RLAY Relay Therapeutics, Inc.DNTH Dianthus Therapeutics, Inc.CRMD CorMedix Inc.ALT Altimmune, Inc.ABUS Arbutus Biopharma CorporationSPRY ARS Pharmaceuticals, Inc.AVDL Avadel Pharmaceuticals plcCRTS Cartesian Therapeutics, Inc.TRDA Entrada Therapeutics, Inc.EYPT Eyepoint Pharmaceuticals, Inc.IMNM Immunome, Inc.LQDA Liquidia CorporationPLRX Pliant Therapeutics, Inc.PRAX Praxis Precision Medicines, Inc.PRTA Prothena Corporation plcSTOK Stoke Therapeutics, Inc.SNDX Syndax Pharmaceuticals, Inc.TSHA Taysha Gene Therapies, Inc.URGN UroGen Pharma Ltd.GOSS Gossamer Bio, Inc.TNGX Tango Therapeutics, Inc.
Peer reciprocity
The companies Lexicon Pharmaceuticals, Inc names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Stoke Therapeutics, Inc. | 2025 | Ian Smith | $170,625 | $11,590,000 | $14,035,067 | $0 | $27,031,655 |
| 2 | Dianthus Therapeutics, Inc. | 2025 | Marino Garcia | 630,000 | 0 | 9,450,952 | 519,750 | 10,614,702 |
| 3 | ARS Pharmaceuticals, Inc. | 2025 | Richard Lowenthal | 700,000 | — | 6,176,110 | 315,000 | 9,656,400 |
| 4 | Praxis Precision Medicines, Inc. | 2025 | Marcio Souza | 659,200 | 2,368,125 | 3,691,125 | 1,483,200 | 8,708,648 |
| 5 | Altimmune, Inc. | 2025 | Vipin Garg | 658,694 | 1,153,600 | 4,812,167 | 357,753 | 8,026,590 |
| 6 | Liquidia Corporation | 2025 | Roger Jeffs | 824,000 | 5,590,992 | 0 | 1,254,400 | 7,712,736 |
| 7 | Immunome, Inc. | 2025 | Clay Siegall | 735,000 | 0 | 6,272,810 | 661,500 | 7,682,601 |
| 8 | Avadel Pharmaceuticals plc | 2024 | Gregory Divis | 651,600 | 0 | 6,722,205 | 0 | 7,399,605 |
| 9 | Syndax Pharmaceuticals, Inc. | 2025 | Michael Metzger | 754,300 | 2,021,965 | 3,454,360 | 848,588 | 7,089,213 |
| 10 | AnaptysBio, Inc. | 2025 | Daniel Faga | 706,011 | 1,592,001 | 3,345,653 | 465,968 | 6,133,943 |
| 11 | CorMedix Inc. | 2025 | Joseph Todisco | 684,353 | 4,492,500 | 0 | 865,072 | 6,101,176 |
| 12 | Prothena Corporation plc | 2025 | Gene Kinney | 692,973 | 961,800 | 3,809,738 | 415,784 | 5,896,045 |
| 13 | Eyepoint Pharmaceuticals, Inc. | 2025 | Jay Duker | 696,251 | 1,610,700 | 2,604,113 | 632,700 | 5,568,352 |
| 14 | Pliant Therapeutics, Inc. | 2025 | Bernard Coulie | 682,000 | 1,810,250 | 2,713,750 | 204,600 | 5,462,901 |
| 15 | Relay Therapeutics, Inc. | 2025 | Sanjiv Patel | 707,846 | 0 | 3,513,900 | 424,708 | 4,646,454 |
| 16 | UroGen Pharma Ltd. | 2025 | Elizabeth Barrett | 855,590 | 2,122,211 | 0 | 516,263 | 4,310,624 |
| 17 | Taysha Gene Therapies, Inc. | 2025 | Sean Nolan | 645,840 | 1,651,125 | 1,258,425 | 542,506 | 4,099,065 |
| 18 | Entrada Therapeutics, Inc. | 2025 | Dipal Doshi | 635,000 | 1,387,428 | 1,452,059 | 349,250 | 3,837,737 |
| 19 | Lexicon Pharmaceuticals, Inc | 2025 | Michael Exton | 650,576 | 1,049,304 | 1,355,231 | 0 | 3,553,953 |
| 20 | Tango Therapeutics, Inc. | 2025 | Barbara Weber | 697,950 | 308,096 | 1,275,328 | 524,250 | 2,823,992 |
| 21 | Gossamer Bio, Inc. | 2025 | Faheem Hasnain | 649,649 | 0 | 1,392,006 | 254,800 | 2,300,455 |
| 22 | Arbutus Biopharma Corporation | 2025 | Lindsay Androski | 437,750 | 0 | 714,751 | 216,512 | 1,369,013 |
| — | Cartesian Therapeutics, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Lexicon Pharmaceuticals, Inc | not disclosed | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Altimmune, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| AnaptysBio, Inc. | 110% | not disclosed | No | Alpine Rewards |
| Arbutus Biopharma Corporation | 110% of target% | not disclosed | not disclosed | Radford (Aon) |
| ARS Pharmaceuticals, Inc. | not disclosed | Option 100 | not disclosed | Aon |
| Avadel Pharmaceuticals plc | not disclosed | not disclosed | not disclosed | Aon |
| Cartesian Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| CorMedix Inc. | not disclosed | not disclosed | not disclosed | Frederic W. Cook & Co. |
| Dianthus Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Alpine Rewards, LLC |
| Entrada Therapeutics, Inc. | not disclosed | not disclosed | No | Pay Governance |
| Eyepoint Pharmaceuticals, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Gossamer Bio, Inc. | 65% | not disclosed | No | Alpine Rewards |
| Immunome, Inc. | 150% | Options 100 | not disclosed | Aon |
| Liquidia Corporation | not disclosed | RSU 50 · PSU 50 | not disclosed | FW Cook |
| Pliant Therapeutics, Inc. | not disclosed | Option 66.67 · RSU 33.33 | not disclosed | Pearl Meyer; Alpine Rewards |
| Praxis Precision Medicines, Inc. | not disclosed | Option 50 · RSU 50 | not disclosed | Frederic W. Cook & Co., Inc. |
| Prothena Corporation plc | 100% | not disclosed | not disclosed | Pay Governance LLC |
| Relay Therapeutics, Inc. | 100% | Options 100 | not disclosed | Aon |
| Stoke Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Syndax Pharmaceuticals, Inc. | 150% | Options 34 · PSU 33 · RSU 33 | Yes — Company's three-year total shareholder return (TSR) as measured against the Nasdaq Biotechnology Index components TSRs | Aon |
| Tango Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Pearl Meyer |
| Taysha Gene Therapies, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| UroGen Pharma Ltd. | 80% | RSU 50 · PSU 50 | No | Compensia, Inc. |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-04-30 | 294,969,542 | 6,947,006 | 506,614 | 97.7% | Passed |
| 2025 | 2025-06-02 | 220,515,663 | 7,898,306 | 1,162,579 | 96.54% | Passed |
| 2024 | 2024-05-10 | 253,593,322 | 6,203,593 | 623,318 | 97.61% | Passed |
| 2023 | 2023-04-27 | 110,285,867 | 24,701,050 | 16,253,209 | 81.7% | Passed |
| 2022 | 2022-05-20 | 106,000,751 | 14,341,221 | 293,763 | 87.87% | Passed |
| 2021 | 2021-04-29 | 94,641,717 | 18,373,001 | 602,692 | 83.3% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-04-30 | 97.7%a |
| 2025 | 2025-06-02 | 96.54%b |
| 2024 | 2024-05-10 | 97.61%c |
a. Approved under the standard stated in the filing — “Any abstention from voting or broker non-vote with respect to such matter will not count as a vote for or against such matter and will not affect the outcome of the proposal.”.
b. Approved under the standard stated in the filing — “Any abstention from voting or broker non-vote with respect to such matter will not count as a vote for or against the amendment and will not affect the outcome of the proposal.”.
c. Approved under the standard stated in the filing — “Any abstention from voting or broker non-vote with respect to such matter will not count as a vote for or against such matter and will not affect the outcome of the proposal.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 13 : 1 |
|---|---|
| CEO total compensation | $3,553,953 |
| Median employee compensation | $282,707 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Artal Participations S.a r.l. | Director | 2026-04-30 | D | 408,434.7 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Artal Participations S.a r.l. | Director | 2026-04-30 | A | 408,434.7 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Artal Participations S.a r.l. | Director | 2026-04-30 | A | 20,421,735 | 0 | 0 | Common, indirect | Form 4 ↗ |
| Raymond Debbane | Director | 2026-05-01 | A | 43,478 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Diane E. Sullivan | Director | 2026-05-01 | A | 35,714 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Judith L. Swain | Director | 2026-05-01 | A | 43,478 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Judith L. Swain | Director | 2026-05-01 | A | 35,714 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sam L. Barker | Director | 2026-05-01 | A | 43,478 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christopher J. Sobecki | Director | 2026-05-01 | A | 43,478 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Philippe J. Amouyal | Director | 2026-05-01 | A | 35,714 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christopher J. Sobecki | Director | 2026-05-01 | A | 35,714 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sam L. Barker | Director | 2026-05-01 | A | 35,714 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Philippe J. Amouyal | Director | 2026-05-01 | A | 43,478 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Diane E. Sullivan | Director | 2026-05-01 | A | 43,478 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Raymond Debbane | Director | 2026-05-01 | A | 35,714 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ivan H. Cheung | Director | 2026-05-01 | A | 43,478 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ivan H. Cheung | Director | 2026-05-01 | A | 35,714 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Raymond Debbane | Director | 2026-06-03 | A | 89,312 | 0 | 0 | Common | Form 4 ↗ |
| Diane E. Sullivan | Director | 2026-06-03 | A | 89,312 | 0 | 0 | Common | Form 4 ↗ |
| Judith L. Swain | Director | 2026-06-03 | A | 89,312 | 0 | 0 | Common | Form 4 ↗ |
| Diane E. Sullivan | Director | 2026-06-03 | D | 89,312 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Philippe J. Amouyal | Director | 2026-06-03 | D | 89,312 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Philippe J. Amouyal | Director | 2026-06-03 | A | 89,312 | 0 | 0 | Common | Form 4 ↗ |
| Sam L. Barker | Director | 2026-06-03 | D | 89,312 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ivan H. Cheung | Director | 2026-06-03 | D | 89,312 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ivan H. Cheung | Director | 2026-06-03 | A | 89,312 | 0 | 0 | Common | Form 4 ↗ |
| Christopher J. Sobecki | Director | 2026-06-03 | A | 89,312 | 0 | 0 | Common | Form 4 ↗ |
| Sam L. Barker | Director | 2026-06-03 | A | 89,312 | 0 | 0 | Common | Form 4 ↗ |
| Raymond Debbane | Director | 2026-06-03 | D | 89,312 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christopher J. Sobecki | Director | 2026-06-03 | D | 89,312 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Judith L. Swain | Director | 2026-06-03 | D | 89,312 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (85 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Michael Exton. DEF 14A, filed 2026-03-16. Section “Summary Compensation Table for 2025” · page 33. As printed: 3,553,953. View filing ↗
- Section 01, Craig Granowitz. DEF 14A, filed 2026-03-16. Section “Summary Compensation Table for 2025”. As printed: 1,755,909. View filing ↗
- Section 01, Scott Coiante. DEF 14A, filed 2026-03-16. Section “Summary Compensation Table for 2025”. As printed: 1,558,246. View filing ↗
- Section 01, Brian Crum. DEF 14A, filed 2026-03-16. Section “Summary Compensation Table for 2025”. As printed: 1,500,384. View filing ↗
- Section 01, Wendy McDermott. DEF 14A, filed 2026-03-16. Section “Summary Compensation Table for 2025”. As printed: 1,270,346. View filing ↗
- Section 03, Scott Coiante OPTION. DEF 14A, filed 2026-03-16. Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Brian Crum OPTION. DEF 14A, filed 2026-03-16. Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Wendy McDermott OPTION. DEF 14A, filed 2026-03-16. Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Scott Coiante OPTION. DEF 14A, filed 2026-03-16. Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Exton RSU. DEF 14A, filed 2026-03-16. Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Brian Crum RSU. DEF 14A, filed 2026-03-16. Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Exton OPTION. DEF 14A, filed 2026-03-16. Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Craig Granowitz OPTION. DEF 14A, filed 2026-03-16. Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Craig Granowitz RSU. DEF 14A, filed 2026-03-16. Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Scott Coiante RSU. DEF 14A, filed 2026-03-16. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Wendy McDermott RSU. DEF 14A, filed 2026-03-16. Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-03-16. Section “CEO Pay Ratio”. As printed: 13 : 1. View filing ↗
- Section 08, Raymond Debbane. DEF 14A, filed 2026-03-16. Section “Director Compensation”. As printed: 196,331. View filing ↗
- Section 08, Samuel L. Barker, Ph.D. DEF 14A, filed 2026-03-16. Section “Director Compensation”. As printed: 188,831. View filing ↗
- Section 08, Philippe J. Amouyal. DEF 14A, filed 2026-03-16. Section “Director Compensation”. As printed: 176,331. View filing ↗
- Section 08, Judith L. Swain, M.D. DEF 14A, filed 2026-03-16. Section “Director Compensation”. As printed: 173,831. View filing ↗
- Section 08, Ivan H. Cheung. DEF 14A, filed 2026-03-16. Section “Director Compensation”. As printed: 171,331. View filing ↗
- Section 08, Diane E. Sullivan. DEF 14A, filed 2026-03-16. Section “Director Compensation”. As printed: 171,331. View filing ↗
- Section 08, Christopher J. Sobecki. DEF 14A, filed 2026-03-16. Section “Director Compensation”. As printed: 161,331. View filing ↗
- Section 08, Michael S. Exton, Ph.D. DEF 14A, filed 2026-03-16. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Artal Participations S.a r.l. 2026-04-30. Form 4, filed 2026-05-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Artal Participations S.a r.l. 2026-04-30. Form 4, filed 2026-05-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Artal Participations S.a r.l. 2026-04-30. Form 4, filed 2026-05-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Raymond Debbane 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Diane E. Sullivan 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Judith L. Swain 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Judith L. Swain 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sam L. Barker 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher J. Sobecki 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Philippe J. Amouyal 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher J. Sobecki 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sam L. Barker 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Philippe J. Amouyal 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Diane E. Sullivan 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Raymond Debbane 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ivan H. Cheung 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ivan H. Cheung 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Raymond Debbane 2026-06-03. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Diane E. Sullivan 2026-06-03. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Judith L. Swain 2026-06-03. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Diane E. Sullivan 2026-06-03. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Philippe J. Amouyal 2026-06-03. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Philippe J. Amouyal 2026-06-03. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sam L. Barker 2026-06-03. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ivan H. Cheung 2026-06-03. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ivan H. Cheung 2026-06-03. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher J. Sobecki 2026-06-03. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sam L. Barker 2026-06-03. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Raymond Debbane 2026-06-03. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher J. Sobecki 2026-06-03. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Judith L. Swain 2026-06-03. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-04-30. Item 5.07 · say-on-pay result. As reported: 97.7% (votes for as printed: 294,969,542). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-03. Item 5.07 · say-on-pay result. As reported: 96.54% (votes for as printed: 220,515,663). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-05-10. Item 5.07 · say-on-pay result. As reported: 97.61% (votes for as printed: 253,593,322). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 460,000 + equity 388,612 + all other 0 = 848,612, summed across the director compensation table rows.
- Stoke Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Stoke Therapeutics, Inc.'s own proxy. As printed: 27,031,655. View filing ↗
- Dianthus Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in Dianthus Therapeutics, Inc.'s own proxy. As printed: 10,614,702. View filing ↗
- ARS Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in ARS Pharmaceuticals, Inc.'s own proxy. As printed: 9,656,400. View filing ↗
- Praxis Precision Medicines, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Praxis Precision Medicines, Inc.'s own proxy. As printed: 8,708,648. View filing ↗
- Altimmune, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-17. CEO total compensation as printed in Altimmune, Inc.'s own proxy. As printed: 8,026,590. View filing ↗
- Liquidia Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Liquidia Corporation's own proxy. As printed: 7,712,736. View filing ↗
- Immunome, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Immunome, Inc.'s own proxy. As printed: 7,682,601. View filing ↗
- Avadel Pharmaceuticals plc, Section 10b CEO total. DEF 14A, filed 2025-06-18. CEO total compensation as printed in Avadel Pharmaceuticals plc's own proxy. As printed: 7,399,605. View filing ↗
- Syndax Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Syndax Pharmaceuticals, Inc.'s own proxy. As printed: 7,089,213. View filing ↗
- AnaptysBio, Inc., Section 10b CEO total. DEF 14A, filed 2026-06-29. CEO total compensation as printed in AnaptysBio, Inc.'s own proxy. As printed: 6,133,943. View filing ↗
- CorMedix Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in CorMedix Inc.'s own proxy. As printed: 6,101,176. View filing ↗
- Prothena Corporation plc, Section 10b CEO total. DEF 14A, filed 2026-03-27. CEO total compensation as printed in Prothena Corporation plc's own proxy. As printed: 5,896,045. View filing ↗
- Eyepoint Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Eyepoint Pharmaceuticals, Inc.'s own proxy. As printed: 5,568,352. View filing ↗
- Pliant Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Pliant Therapeutics, Inc.'s own proxy. As printed: 5,462,901. View filing ↗
- Relay Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Relay Therapeutics, Inc.'s own proxy. As printed: 4,646,454. View filing ↗
- UroGen Pharma Ltd., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in UroGen Pharma Ltd.'s own proxy. As printed: 4,310,624. View filing ↗
- Taysha Gene Therapies, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Taysha Gene Therapies, Inc.'s own proxy. As printed: 4,099,065. View filing ↗
- Entrada Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Entrada Therapeutics, Inc.'s own proxy. As printed: 3,837,737. View filing ↗
- Lexicon Pharmaceuticals, Inc (subject), Section 10b CEO total. DEF 14A, filed 2026-03-16. CEO total compensation as printed in Lexicon Pharmaceuticals, Inc's own proxy. As printed: 3,553,953. View filing ↗
- Tango Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Tango Therapeutics, Inc.'s own proxy. As printed: 2,823,992. View filing ↗
- Gossamer Bio, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Gossamer Bio, Inc.'s own proxy. As printed: 2,300,455. View filing ↗
- Arbutus Biopharma Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-14. CEO total compensation as printed in Arbutus Biopharma Corporation's own proxy. As printed: 1,369,013. View filing ↗
- Section 10a, Syndax Pharmaceuticals, Inc. reciprocity. DEF 14A. Syndax Pharmaceuticals, Inc. names Lexicon Pharmaceuticals, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗